Cantor Fitzgerald Maintains Overweight Rating on Disc Medicine
Cantor Fitzgerald maintained its Overweight rating on Disc Medicine and a $170 price target. The target implies 199.1% upside from the Oct. 16 close of $56.84.
Cantor Fitzgerald maintained its Overweight rating on Disc Medicine and a $170 price target. The target implies 199.1% upside from the Oct. 16 close of $56.84.